Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Obese Mice" patented technology

Antiobesity composition

The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract and Mori Folium extract, and a method for suppressing obesity using the composition. Further, the present invention provides an antiobesity composition comprising extract of Melissa, extract of Artemisia and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract, Artemisia extract and Mori Folium extract, and a method for suppressing obesity using the composition. When the present compositions are administrated into genetically obese mice or high fat diet-induced obese mice, the present compositions reduced body weight, body fat and gonadal fat, and reduce blood cholesterol level and obesity-related blood glucose level. Also, the present compositions suppress hypertrophy of adipocytes, and inhibit the accumulation of lipid in the liver by reducing the size and number of lipid vacuoles. Furthermore, in human clinial trial the present compositions show that body weight, PIBW, body fat, especially visceral fat, apolipoprotin B concentration, ratio of total cholesterol/HDL cholesterol and ratio of LDL cholesterol/HDL cholesterol are significantly decreased, and atherogenic index is improved and muscle mass is increased. Thus, the present compositions can be usefully applied as antiobesity composition for reduction of body weight and suppression of abdominal fat, particularly, visceral fat.
Owner:ANGIOLAB

Diethylstilbestrol compound and application thereof in preparation of drug for treating osteoporosis and hyperlipemia

InactiveCN103351285ADecreased lipid metabolismAbnormally decreased lipid metabolismEther separation/purificationMetabolism disorderBone densityLow density lipoprotein cholesterol
The invention discloses a diethylstilbestrol compound and application thereof in preparation of a drug for treating osteoporosis and/or hyperlipemia. The structural formula of the diethylstilbestrol compound is shown in the specification. The data of a cellular level pharmacodynamic test show that cajanstilbene H (R is H, and X is Cl) can promote multiplication and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) of an SD rat. After an ob/ob obese mice orally takes the cajanstilbene H (20 mg/kg/d) continuously for 21 days, the results are as follows: (1) no obvious effect on weight is generated; (2) the bone density of the mice is obviously increased; serum alkaline phosphatase (ALP) and tartrate resistant acid phosphatase (TRACP) level are obviously reduced; and the serum calcium concentration is improved; and (3) levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in the serum of the mice are obviously reduced. The results show that the cajanstilbene H has positive significance in treatment of the osteoporosis caused by obesity and high blood sugar, and has a clear curative effect on the aspect of improvement of lipid metabolism of the obese mice. The cajanstilbene H has a clear treatment effect on the osteoporosis caused by obesity and high blood sugar and simultaneously can improve lipid metabolism; and metabasis of hyperlipemia to diabetes mellitus to chronic complication of diabetes mellitus to osteoporosis can be avoided to a certain extent.
Owner:广州中医药大学热带医学研究所 +1

Preparation method and application of cordyceps active oligosaccharide

The invention provides a preparation method and application of cordyceps active oligosaccharide, and belongs to the technical field of functional dietary fiber preparation. According to the preparation method, the cordyceps active oligosaccharide is composed of the components of glucose, galactose, mannose and rhamnose according to the weight ratio of 1-10:2-10:1-20:0.2-2; the glucose, the galactose, the mannose and the rhamnose are raw material carbohydrate and are formed through compound reaction of monosaccaride under the action of an electromagnetic field and an acid catalyst, and the bond types of the glucose, the galactose, the mannose and the rhamnose are main 1-3, 1-6 and 1-2. The preparation method has the advantages of being fast in synthetic speed, free of waste liquid, less in side reaction, friendly to environment and high in yield. The molecular weight of the cordyceps active oligosaccharide reaches 0.7-4 kDa, and the polymerization degree of cordyceps active oligosaccharide reaches 4-22. Biological experiments prove that the cordyceps active oligosaccharide has the better vitro antioxidant property and can promote probiotics to proliferate; after being taken orally, the cordyceps active oligosaccharide can lower blood lipid of obese mice, regulate intestinal flora and boost immunity, and has a certain anti-obesity effect.
Owner:JIANGNAN UNIV

Application of spermidine in preparation of preparation for improving bacterial abundance of lachnospiraceae

InactiveCN111617061AIncrease abundanceImprove intestinal barrier function damageOrganic active ingredientsMetabolism disorderDiseaseFat mouse
The invention discloses an application of spermidine in preparation of a preparation for improving the bacterial abundance of lachnospiraceae. The bacterial abundance of the lachnospiraceae NK4A136 group in the intestinal tract of an obese mouse can be remarkably improved by taking in exogenous spermidine, and the intestinal tract barrier function damage induced by metabolism related diseases suchas obesity is improved.
Owner:ZHEJIANG UNIV OF TECH

Uses of triptolide for treating obesity and fatty liver

The present invention relates to the field of medicines, particularly relates to uses of triptolide for treating obesity and fatty liver, and specifically relates to applications of the triptolide inpreparation of drugs for treating and / or preventing the obesity and fatty liver. Experimental results show that after the treatment by the triptolide, the body weight, the fat accumulation, the liverfat production and liver coefficients of obese mice with high fat diet can be significantly reduced, and ALT, AST, LDL and CHO1 content in blood of the obese mice with the high fat diet are reduced, indicating that the triptolide has therapeutic effects on the obesity and fatty liver.
Owner:SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products